Avelumab and Merkel Cell Carcinoma: Prognosis, Recovery, and Management

From General Skin Health to Occupational Safety

The legacy of general health and science information has long emphasized the importance of skin care as a cornerstone of wellness and longevity. Within this broad domain, anti-aging practices have evolved from basic hygiene to a sophisticated, multi-billion dollar industry focused on preserving skin integrity and function. This foundational knowledge established the skin as a critical interface between the body and the environment, highlighting the need for protective measures against external stressors. Building on this heritage, occupational health contexts now demand a more targeted examination of specific exposures that may compromise skin health. In particular, the transition from general skin care to occupational safety involves scrutinizing agents encountered in professional settings. One such agent is Avelumab, a therapeutic monoclonal antibody used in oncology. For workers involved in its production, handling, or administration, the potential for dermal exposure raises important questions. This concern is especially relevant when considering the link between Avelumab and the management of Merkel Cell Carcinoma, a rare but aggressive skin cancer. The occupational exposure concern thus pivots from general skin health maintenance to the specific risks associated with handling this biologic agent, necessitating rigorous safety protocols and monitoring to prevent unintended health consequences in the workplace.

Avelumab: Mechanism and Clinical Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors (ICIs), including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). In Europe, approved systemic therapies for metastatic MCC are limited to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Prognosis and Management of Avelumab-Refractory Merkel Cell Carcinoma

Retrospective studies have explored the use of combined ipilimumab plus nivolumab in avelumab-refractory MCC. In one study at three German sites, three out of five patients treated with combined ipilimumab plus nivolumab responded according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further noted that despite advances, about half of patients progress on ICI therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). A case report described the first documented instance of hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). The hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the potential for avelumab to trigger immune-mediated complications beyond typical irAEs, which may require careful monitoring and management. Regarding risk anchors, the adequacy of warnings about avelumab and MCC is supported by the drug's approval based on clinical trial data demonstrating efficacy in a specific patient population (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the evidence indicates that approximately half of patients do not respond or eventually progress on ICI therapy, underscoring the need for clear communication about prognosis and treatment limitations (https://pubmed.ncbi.nlm.nih.gov/35877101/). Prognosis-related considerations for affected patients include the aggressive nature of MCC, the potential for durable responses with avelumab, and the possibility of immune-related adverse events that may require intervention (https://pubmed.ncbi.nlm.nih.gov/31543781/). The timeline between exposure to avelumab and documented harm, such as immune-related adverse events, can vary; in the reported case of sarcoidosis reactivation, hypercalcemia developed during treatment and resolved with corticosteroids without discontinuation of avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who become refractory to avelumab, subsequent treatment with combined ipilimumab plus nivolumab may offer benefit, but data are limited to small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, avelumab represents a significant therapeutic option for metastatic MCC, with evidence of efficacy in a subset of patients. However, the disease's aggressive nature, the potential for immune-related adverse events, and the lack of effective options for avelumab-refractory patients highlight important considerations for prognosis and management. Ongoing monitoring for irAEs and exploration of alternative immunotherapies remain critical components of care.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the prognosis for Merkel cell carcinoma treated with avelumab?

Avelumab has shown efficacy in approximately one-third of patients with chemotherapy-refractory metastatic Merkel cell carcinoma (MCC), with durable responses in some cases. However, about half of patients with advanced MCC progress on immune checkpoint inhibitor therapy, and the disease carries high rates of recurrence and mortality. Prognosis depends on individual factors, including response to treatment and management of immune-related adverse events.

What are the management options for patients who become refractory to avelumab?

For patients who become refractory to avelumab, limited data suggest that combined ipilimumab plus nivolumab may offer benefit, with responses observed in small retrospective studies. However, efficient and safe treatment options are lacking, and ongoing monitoring for immune-related adverse events is critical. Clinical trials and alternative immunotherapies may be considered.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.